SCHEMBL925179

SCHEMBL925179

O=S(=O)(Nc1cncc(Cl)n1)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.58
POLB P06746 1/20 0.56
CDK2 P24941 2/20 0.54
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPSR1 Q6W5P4 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
SLC40A1 Q9NP59 1/20 0.48
IL1RN P18510 1/20 0.46
KEAP1 Q14145 1/20 0.46
ERAP1 Q9NZ08 1/20 0.46
LMNA P02545 2/20 0.45
PKM P14618 2/20 0.45
CYP2C9 P11712 1/20 0.44
PIK3CD O00329 1/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
PIK3CG P48736 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfaclozine SCHEMBL29393580 0.84 LMNA (0.60) CDK2KDM4EALDH1A1NPSR1LMNA
Sulfaclozine SCHEMBL2109909 0.84 LMNA (0.60) CDK2KDM4EALDH1A1NPSR1LMNA
Sulfaclozine SCHEMBL31317653 0.83 LMNA (0.58) CDK2KDM4EALDH1A1NPSR1LMNA
Sulfaclozine SCHEMBL28407148 0.82 LMNA (0.57) CDK2KDM4EALDH1A1NPSR1LMNA
SCHEMBL6301738 0.81 CA2 (0.49) CDK2NPSR1PIK3CBMEN1KMT2A
SCHEMBL1621377 0.80 KDM4E (0.66) GAAPOLBKDM4EALDH1A1HPGD
SCHEMBL29967512 0.80 KDM4E (0.66) GAAPOLBKDM4EALDH1A1HPGD
SCHEMBL25352139 0.77 GAA (0.58) GAAPOLBKDM4EALDH1A1HPGD
SCHEMBL25351338 0.75 FFAR4 (0.55) GAAPOLBKDM4EALDH1A1HPGD
SCHEMBL24287407 0.74 GAA (0.58) GAAPOLBKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841233-A1 ELECTROLYTE FOR THE CYANIDE-FREE DEPOSITION OF SILVER Umicore Galvanotechnik GmbH (DE) 2021-06-30 EP disclosed
US-7868188-B2 5-heteroaryl thiazoles and their use as PI3K inhibitors ASTRAZENECA AB (SE) 2011-01-11 US disclosed
EP-1841763-B1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS ASTRAZENECA AB (SE) 2010-06-30 EP disclosed
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors ASTRAZENECA AB (SE) 2008-06-05 US disclosed
CN-101098869-A 5-heteroaryl thiazoles and their use as p13k inhibitors ASTRAZENECA AB (SE) 2008-01-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors MTOR, PIK3R5, PIK3CA GAA 646/4885POLB 3561/4885CDK2 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.